| Company Name: |
Shaoyuan Technology (Shanghai) Co., Ltd.
|
| Tel: |
021-50795510 4000665055 |
| Email: |
sy-c6@accelachem.com |
| Products Intro: |
Product Name:3,4-Dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]benzene-1,2-diol
CAS:2097148-94-0
Purity:>=95% Package:0.1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:LXQ46
CAS:2097148-94-0
Package:10mg;50mg
|
|
| | 1,2-Benzenediol, 3,4-dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]- Basic information |
| | 1,2-Benzenediol, 3,4-dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]- Chemical Properties |
| Boiling point | 645.6±65.0 °C(predicted) | | density | 1.626±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 6.30±0.45(predicted) |
| | 1,2-Benzenediol, 3,4-dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]- Usage And Synthesis |
| Uses | LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models[1]. | | References | [1] Li X, et al., Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors. Eur J Med Chem. 2019 Mar 15;166:178-185. DOI:10.1016/j.ejmech.2019.01.057 |
| | 1,2-Benzenediol, 3,4-dibromo-5-[5-[4-(4-ethoxyphenoxy)phenyl]-2-oxazolyl]- Preparation Products And Raw materials |
|